{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T04:41:27Z","timestamp":1790224887476,"version":"4.1.0"},"reference-count":122,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,4,1]],"date-time":"2017-04-01T00:00:00Z","timestamp":1491004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,4,1]],"date-time":"2017-04-01T00:00:00Z","timestamp":1491004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2017,4,1]],"date-time":"2017-04-01T00:00:00Z","timestamp":1491004800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2017,4,1]],"date-time":"2017-04-01T00:00:00Z","timestamp":1491004800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2017,4,1]],"date-time":"2017-04-01T00:00:00Z","timestamp":1491004800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2017,4,1]],"date-time":"2017-04-01T00:00:00Z","timestamp":1491004800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2017,4,1]],"date-time":"2017-04-01T00:00:00Z","timestamp":1491004800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004731","name":"Natural Science Foundation of Zhejiang Province","doi-asserted-by":"publisher","award":["LY15H030011"],"award-info":[{"award-number":["LY15H030011"]}],"id":[{"id":"10.13039\/501100004731","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine & Pharmacotherapy"],"published-print":{"date-parts":[[2017,4]]},"DOI":"10.1016\/j.biopha.2017.01.107","type":"journal-article","created":{"date-parts":[[2017,1,22]],"date-time":"2017-01-22T12:30:26Z","timestamp":1485088226000},"page":"459-468","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":65,"special_numbering":"C","title":["Sorafenib: A potential therapeutic drug for hepatic fibrosis and its outcomes"],"prefix":"10.1016","volume":"88","author":[{"given":"Rui","family":"Ma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuelong","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuang","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linghua","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiujun","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.biopha.2017.01.107_bib0005","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.bpg.2011.02.005","article-title":"Mechanisms of hepatic fibrogenesis","volume":"25","author":"Lee","year":"2011","journal-title":"Best Pract. Res. Clin. Gastroenterol."},{"issue":"7","key":"10.1016\/j.biopha.2017.01.107_bib0010","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1053\/j.gastro.2012.04.001","article-title":"The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology","volume":"142","author":"Chalasani","year":"2012","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.biopha.2017.01.107_bib0015","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1136\/gutjnl-2011-300342","article-title":"Prevalence of non-alcoholic fatty liver disease and advanced fibrosis in Hong Kong Chinese: a population study using proton-magnetic resonance spectroscopy and transient elastography","volume":"61","author":"Wong","year":"2012","journal-title":"Gut"},{"issue":"4","key":"10.1016\/j.biopha.2017.01.107_bib0020","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.cgh.2014.04.014","article-title":"Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies","volume":"13","author":"Singh","year":"2015","journal-title":"Clin. Gastroenterol. Hepatol."},{"issue":"2","key":"10.1016\/j.biopha.2017.01.107_bib0025","first-page":"124","article-title":"What is the treatment of choice in a patient with liver cirrhosis and esophageal varices that have bled to prevent rebleeding: beta-blockers, endoscopic ligation or both?","volume":"32","author":"Albillos Martinez","year":"2009","journal-title":"Gastroenterol. Hepatol."},{"issue":"5","key":"10.1016\/j.biopha.2017.01.107_bib0030","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1586\/eri.09.28","article-title":"Treatment of HBV-related cirrhosis","volume":"7","author":"Vallet-Pichard","year":"2009","journal-title":"Expert Rev. Anti Infect. Ther."},{"issue":"4","key":"10.1016\/j.biopha.2017.01.107_bib0035","first-page":"278","article-title":"The risk and predictive factors for developing liver cancer among patients with decompensated liver cirrhosis","volume":"22","author":"Kato","year":"1992","journal-title":"Jpn. J. Clin. Oncol."},{"key":"10.1016\/j.biopha.2017.01.107_bib0040","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/S0076-6879(05)07047-3","article-title":"Sorafenib (BAY 43\u20139006 Nexavar), a dual-action inhibitor that targets RAF\/MEK\/ERK pathway in tumor cells and tyrosine kinases VEGFR\/PDGFR in tumor vasculature","volume":"407","author":"Adnane","year":"2006","journal-title":"Methods Enzymol."},{"issue":"10","key":"10.1016\/j.biopha.2017.01.107_bib0045","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1038\/nrd2130","article-title":"Discovery and development of sorafenib: a multikinase inhibitor for treating cancer","volume":"5","author":"Wilhelm","year":"2006","journal-title":"Nat. Rev. Drug Discov."},{"issue":"19","key":"10.1016\/j.biopha.2017.01.107_bib0050","doi-asserted-by":"crossref","first-page":"7099","DOI":"10.1158\/0008-5472.CAN-04-1443","article-title":"BAY 43\u20139006 exhibits broad spectrum oral antitumor activity and targets the RAF\/MEK\/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis","volume":"64","author":"Wilhelm","year":"2004","journal-title":"Cancer Res."},{"issue":"10","key":"10.1016\/j.biopha.2017.01.107_bib0055","doi-asserted-by":"crossref","first-page":"3129","DOI":"10.1158\/1535-7163.MCT-08-0013","article-title":"Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling","volume":"7","author":"Wilhelm","year":"2008","journal-title":"Mol. Cancer Ther."},{"issue":"4","key":"10.1016\/j.biopha.2017.01.107_bib0060","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in advanced hepatocellular carcinoma","volume":"359","author":"Llovet","year":"2008","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.biopha.2017.01.107_bib0065","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa060655","article-title":"Sorafenib in advanced clear-cell renal-cell carcinoma","volume":"356","author":"Escudier","year":"2007","journal-title":"N. Engl. J. Med."},{"issue":"24","key":"10.1016\/j.biopha.2017.01.107_bib0070","doi-asserted-by":"crossref","first-page":"11851","DOI":"10.1158\/0008-5472.CAN-06-1377","article-title":"Sorafenib blocks the RAF\/MEK\/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC\/PRF\/5","volume":"66","author":"Liu","year":"2006","journal-title":"Cancer Res."},{"issue":"4","key":"10.1016\/j.biopha.2017.01.107_bib0075","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1002\/hep.22758","article-title":"Beneficial effects of sorafenib on splanchnic, intrahepatic, and portocollateral circulations in portal hypertensive and cirrhotic rats","volume":"49","author":"Mejias","year":"2009","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.biopha.2017.01.107_bib0080","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/j.jhep.2009.06.024","article-title":"Sorafenib attenuates the portal hypertensive syndrome in partial portal vein ligated rats","volume":"51","author":"Reiberger","year":"2009","journal-title":"J. Hepatol."},{"issue":"2","key":"10.1016\/j.biopha.2017.01.107_bib0085","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1111\/j.1476-5381.2009.00158.x","article-title":"Sorafenib targets dysregulated Rho kinase expression and portal hypertension in rats with secondary biliary cirrhosis","volume":"157","author":"Hennenberg","year":"2009","journal-title":"Br. J. Pharmacol."},{"issue":"1","key":"10.1016\/j.biopha.2017.01.107_bib0090","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.jhep.2010.02.027","article-title":"New insights into the antifibrotic effects of sorafenib on hepatic stellate cells and liver fibrosis","volume":"53","author":"Wang","year":"2010","journal-title":"J. Hepatol."},{"issue":"2","key":"10.1016\/j.biopha.2017.01.107_bib0095","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/labinvest.2010.148","article-title":"Hepatic and HSC-specific sorafenib effects in rats with established secondary biliary cirrhosis","volume":"91","author":"Hennenberg","year":"2011","journal-title":"Lab. Invest."},{"issue":"1","key":"10.1016\/j.biopha.2017.01.107_bib0100","first-page":"257","article-title":"Antifibrotic activity of sorafenib in experimental hepatic fibrosis: refinement of inhibitory targets, dosing, and window of efficacy in vivo","volume":"58","author":"Hong","year":"2013","journal-title":"Dig. Dis. Sci."},{"issue":"23","key":"10.1016\/j.biopha.2017.01.107_bib0105","doi-asserted-by":"crossref","first-page":"7243","DOI":"10.1073\/pnas.1507499112","article-title":"Sorafenib and its derivative SC-1 exhibit antifibrotic effects through signal transducer and activator of transcription 3 inhibition","volume":"112","author":"Su","year":"2015","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"2","key":"10.1016\/j.biopha.2017.01.107_bib0110","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1172\/JCI24282","article-title":"Liver fibrosis","volume":"115","author":"Bataller","year":"2005","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.biopha.2017.01.107_bib0115","first-page":"1","article-title":"Cooperation of liver cells in health and disease","volume":"161","author":"Kmiec","year":"2001","journal-title":"Adv. Anat. Embryol. Cell Biol."},{"issue":"3","key":"10.1016\/j.biopha.2017.01.107_bib0120","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/nri3623","article-title":"Liver fibrosis and repair: immune regulation of wound healing in a solid organ","volume":"14","author":"Pellicoro","year":"2014","journal-title":"Nat. Rev. Immunol."},{"issue":"6","key":"10.1016\/j.biopha.2017.01.107_bib0125","doi-asserted-by":"crossref","first-page":"483","DOI":"10.2174\/1566524033479528","article-title":"Mechanisms of liver injury: an overview","volume":"3","author":"Higuchi","year":"2003","journal-title":"Curr. Mol. Med."},{"issue":"2","key":"10.1016\/j.biopha.2017.01.107_bib0130","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1002\/hep.20051","article-title":"Apoptosis: the nexus of liver injury and fibrosis","volume":"39","author":"Canbay","year":"2004","journal-title":"Hepatology"},{"issue":"32","key":"10.1016\/j.biopha.2017.01.107_bib0135","doi-asserted-by":"crossref","first-page":"23337","DOI":"10.1074\/jbc.M700194200","article-title":"Fibroblasts derive from hepatocytes in liver fibrosis via epithelial to mesenchymal transition","volume":"282","author":"Zeisberg","year":"2007","journal-title":"J. Biol. Chem."},{"issue":"3","key":"10.1016\/j.biopha.2017.01.107_bib0140","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1002\/hep.23368","article-title":"Hepatocytes do not undergo epithelial-mesenchymal transition in liver fibrosis in mice","volume":"51","author":"Taura","year":"2010","journal-title":"Hepatology"},{"issue":"37","key":"10.1016\/j.biopha.2017.01.107_bib0145","doi-asserted-by":"crossref","first-page":"5764","DOI":"10.1038\/sj.onc.1208927","article-title":"TGF-beta and epithelial-to-mesenchymal transitions","volume":"24","author":"Zavadil","year":"2005","journal-title":"Oncogene"},{"issue":"5","key":"10.1016\/j.biopha.2017.01.107_bib0150","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1002\/hep.24254","article-title":"Sorafenib inhibits transforming growth factor beta1-mediated epithelial-mesenchymal transition and apoptosis in mouse hepatocytes","volume":"53","author":"Chen","year":"2011","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.biopha.2017.01.107_bib0155","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1053\/jhep.2001.28457","article-title":"Transforming growth factor beta and the liver","volume":"34","author":"Bissell","year":"2001","journal-title":"Hepatology"},{"issue":"12","key":"10.1016\/j.biopha.2017.01.107_bib0160","doi-asserted-by":"crossref","first-page":"5408","DOI":"10.1073\/pnas.89.12.5408","article-title":"Induction of apoptosis in cultured hepatocytes and in regressing liver by transforming growth factor beta 1","volume":"89","author":"Oberhammer","year":"1992","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"6","key":"10.1016\/j.biopha.2017.01.107_bib0165","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/S0092-8674(03)00432-X","article-title":"Mechanisms of TGF-beta signaling from cell membrane to the nucleus","volume":"113","author":"Shi","year":"2003","journal-title":"Cell"},{"issue":"6","key":"10.1016\/j.biopha.2017.01.107_bib0170","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1101\/gad.14.6.627","article-title":"Controlling TGF-beta signaling","volume":"14","author":"Massague","year":"2000","journal-title":"Genes Dev."},{"issue":"5","key":"10.1016\/j.biopha.2017.01.107_bib0175","doi-asserted-by":"crossref","first-page":"2236","DOI":"10.2353\/ajpath.2010.090469","article-title":"Lack of glycoprotein 130\/signal transducer and activator of transcription 3-mediated signaling in hepatocytes enhances chronic liver injury and fibrosis progression in a model of sclerosing cholangitis","volume":"176","author":"Plum","year":"2010","journal-title":"Am. J. Pathol."},{"issue":"7","key":"10.1016\/j.biopha.2017.01.107_bib0180","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1053\/j.gastro.2010.02.049","article-title":"Signal transducer and activator of transcription 3 protects from liver injury and fibrosis in a mouse model of sclerosing cholangitis","volume":"138","author":"Mair","year":"2010","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1016\/j.biopha.2017.01.107_bib0185","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1002\/hep.23532","article-title":"Dissociation between liver inflammation and hepatocellular damage induced by carbon tetrachloride in myeloid cell-specific signal transducer and activator of transcription 3 gene knockout mice","volume":"51","author":"Horiguchi","year":"2010","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.biopha.2017.01.107_bib0190","doi-asserted-by":"crossref","first-page":"536","DOI":"10.7150\/ijbs.7.536","article-title":"Signal transducer and activator of transcription 3 in liver diseases: a novel therapeutic target","volume":"7","author":"Wang","year":"2011","journal-title":"Int. J. Biol. Sci."},{"issue":"5","key":"10.1016\/j.biopha.2017.01.107_bib0195","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1093\/intimm\/dxq030","article-title":"IL-6: from its discovery to clinical applications","volume":"22","author":"Kishimoto","year":"2010","journal-title":"Int. Immunol."},{"key":"10.1016\/j.biopha.2017.01.107_bib0200","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jaut.2013.07.008","article-title":"STAT3-mediated attenuation of CCl4-induced mouse liver fibrosis by the protein kinase inhibitor sorafenib","volume":"46","author":"Deng","year":"2013","journal-title":"J. Autoimmun."},{"issue":"21","key":"10.1016\/j.biopha.2017.01.107_bib0205","doi-asserted-by":"crossref","first-page":"5189","DOI":"10.1158\/1078-0432.CCR-09-3389","article-title":"Sorafenib overcomes TRAIL resistance of hepatocellular carcinoma cells through the inhibition of STAT3","volume":"16","author":"Chen","year":"2010","journal-title":"Clin. Cancer Res."},{"issue":"11","key":"10.1016\/j.biopha.2017.01.107_bib0210","doi-asserted-by":"crossref","first-page":"3519","DOI":"10.1158\/1535-7163.MCT-08-0138","article-title":"Sorafenib inhibits signal transducer and activator of transcription 3 signaling associated with growth arrest and apoptosis of medulloblastomas","volume":"7","author":"Yang","year":"2008","journal-title":"Mol. Cancer Ther."},{"issue":"6","key":"10.1016\/j.biopha.2017.01.107_bib0215","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1002\/hep.23214","article-title":"Sorafenib inhibits signal transducer and activator of transcription-3 signaling in cholangiocarcinoma cells by activating the phosphatase shatterproof 2","volume":"50","author":"Blechacz","year":"2009","journal-title":"Hepatology"},{"issue":"9","key":"10.1016\/j.biopha.2017.01.107_bib0220","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1136\/gut.2005.081059","article-title":"Intrahepatic upregulation of RhoA and Rho-kinase signalling contributes to increased hepatic vascular resistance in rats with secondary biliary cirrhosis","volume":"55","author":"Zhou","year":"2006","journal-title":"Gut"},{"issue":"1","key":"10.1016\/j.biopha.2017.01.107_bib0225","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1002\/hep.21673","article-title":"Atorvastatin lowers portal pressure in cirrhotic rats by inhibition of RhoA\/Rho-kinase and activation of endothelial nitric oxide synthase","volume":"46","author":"Trebicka","year":"2007","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.biopha.2017.01.107_bib0230","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1136\/gut.50.4.571","article-title":"Hepatic stellate cells: role in microcirculation and pathophysiology of portal hypertension","volume":"50","author":"Reynaert","year":"2002","journal-title":"Gut"},{"issue":"6","key":"10.1016\/j.biopha.2017.01.107_bib0235","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1053\/j.gastro.2008.03.003","article-title":"Mechanisms of hepatic fibrogenesis","volume":"134","author":"Friedman","year":"2008","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.biopha.2017.01.107_bib0240","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1002\/hep.21564","article-title":"Sinusoidal remodeling and angiogenesis: a new function for the liver-specific pericyte?","volume":"45","author":"Lee","year":"2007","journal-title":"Hepatology"},{"issue":"10","key":"10.1016\/j.biopha.2017.01.107_bib0245","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.4161\/cbt.7.10.6623","article-title":"Vorinostat and sorafenib increase ER stress, autophagy and apoptosis via ceramide-dependent CD95 and PERK activation","volume":"7","author":"Park","year":"2008","journal-title":"Cancer Biol. Ther."},{"issue":"2","key":"10.1016\/j.biopha.2017.01.107_bib0250","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1002\/hep.24427","article-title":"Complementary vascular and matrix regulatory pathways underlie the beneficial mechanism of action of sorafenib in liver fibrosis","volume":"54","author":"Thabut","year":"2011","journal-title":"Hepatology"},{"issue":"12","key":"10.1016\/j.biopha.2017.01.107_bib0255","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1038\/sj.eye.6702716","article-title":"Strengthening tight junctions of retinal microvascular endothelial cells by pericytes under normoxia and hypoxia involving angiopoietin-1 signal way","volume":"21","author":"Wang","year":"2007","journal-title":"Eye"},{"issue":"5","key":"10.1016\/j.biopha.2017.01.107_bib0260","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1053\/j.gastro.2008.07.065","article-title":"Hepatic stellate cells secrete angiopoietin 1 that induces angiogenesis in liver fibrosis","volume":"135","author":"Taura","year":"2008","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1016\/j.biopha.2017.01.107_bib0265","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1002\/hep.21921","article-title":"Antiangiogenic treatment with sunitinib ameliorates inflammatory infiltrate, fibrosis, and portal pressure in cirrhotic rats","volume":"46","author":"Tugues","year":"2007","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.biopha.2017.01.107_bib0270","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1002\/hep.20965","article-title":"Upregulation of proinflammatory and proangiogenic cytokines by leptin in human hepatic stellate cells","volume":"42","author":"Aleffi","year":"2005","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.biopha.2017.01.107_bib0275","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1083\/jcb.132.6.1177","article-title":"Cooperative effect of TNFalpha, bFGF, and VEGF on the formation of tubular structures of human microvascular endothelial cells in a fibrin matrix Role of urokinase activity","volume":"132","author":"Koolwijk","year":"1996","journal-title":"J. Cell Biol."},{"issue":"11","key":"10.1016\/j.biopha.2017.01.107_bib0280","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1096\/fj.02-0134fje","article-title":"Interleukin-1alpha promotes angiogenesis in vivo via VEGFR-2 pathway by inducing inflammatory cell VEGF synthesis and secretion","volume":"16","author":"Salven","year":"2002","journal-title":"FASEB J."},{"issue":"6","key":"10.1016\/j.biopha.2017.01.107_bib0285","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1096\/fasebj.11.6.9194526","article-title":"The codependence of angiogenesis and chronic inflammation","volume":"11","author":"Jackson","year":"1997","journal-title":"FASEB J."},{"issue":"6","key":"10.1016\/j.biopha.2017.01.107_bib0290","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1038\/nm0603-685","article-title":"Molecular regulation of vessel maturation","volume":"9","author":"Jain","year":"2003","journal-title":"Nat. Med."},{"issue":"2","key":"10.1016\/j.biopha.2017.01.107_bib0295","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.cyto.2012.05.001","article-title":"Evaluation of inflammatory and angiogenic factors in patients with non-alcoholic fatty liver disease","volume":"59","author":"Coulon","year":"2012","journal-title":"Cytokine"},{"issue":"2","key":"10.1016\/j.biopha.2017.01.107_bib0300","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1007\/s12291-011-0121-7","article-title":"Role of cytokines in the pathogenesis of non-alcoholic Fatty liver disease","volume":"26","author":"Das","year":"2011","journal-title":"Indian J. Clin. Biochem."},{"issue":"5","key":"10.1016\/j.biopha.2017.01.107_bib0305","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1590\/1414-431x20143962","article-title":"Sorafenib prevents liver fibrosis in a non-alcoholic steatohepatitis (NASH) rodent model","volume":"48","author":"Stefano","year":"2015","journal-title":"Braz. J. Med. Biol. Res."},{"issue":"2","key":"10.1016\/j.biopha.2017.01.107_bib0310","first-page":"361","article-title":"Neutrophil-derived superoxide anion induces lipid peroxidation and stimulates collagen synthesis in human hepatic stellate cells: role of nitric oxide","volume":"25","author":"Casini","year":"1997","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.biopha.2017.01.107_bib0315","first-page":"919","article-title":"Human hepatic stellate cells show features of antigen-presenting cells and stimulate lymphocyte proliferation","volume":"38","author":"Vinas","year":"2003","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.biopha.2017.01.107_bib0320","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/S0168-8278(00)80272-X","article-title":"Effects of lipopolysaccharide on TNF-alpha production, hepatic NOS2 activity, and hepatic toxicity in rats with cirrhosis","volume":"33","author":"Heller","year":"2000","journal-title":"J. Hepatol."},{"issue":"2","key":"10.1016\/j.biopha.2017.01.107_bib0325","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1074\/jbc.271.2.736","article-title":"Interleukin 6 induces the expression of vascular endothelial growth factor","volume":"271","author":"Cohen","year":"1996","journal-title":"J. Biol. Chem."},{"issue":"6","key":"10.1016\/j.biopha.2017.01.107_bib0330","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1111\/j.1572-0241.2007.01774.x","article-title":"Increased hepatic and circulating interleukin-6 levels in human nonalcoholic steatohepatitis","volume":"103","author":"Wieckowska","year":"2008","journal-title":"Am. J. Gastroenterol."},{"issue":"3","key":"10.1016\/j.biopha.2017.01.107_bib0335","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1053\/j.gastro.2012.05.049","article-title":"Interleukin-17 signaling in inflammatory, Kupffer cells, and hepatic stellate cells exacerbates liver fibrosis in mice","volume":"143","author":"Meng","year":"2012","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.biopha.2017.01.107_bib0340","doi-asserted-by":"crossref","first-page":"385","DOI":"10.3748\/wjg.v10.i3.385","article-title":"Expression of platelet-derived growth factor-BB in liver tissues of patients with chronic hepatitis B","volume":"10","author":"Lou","year":"2004","journal-title":"World J. Gastroenterol."},{"issue":"9","key":"10.1016\/j.biopha.2017.01.107_bib0345","doi-asserted-by":"crossref","first-page":"3389","DOI":"10.1073\/pnas.0409722102","article-title":"Platelet-derived growth factor C induces liver fibrosis, steatosis, and hepatocellular carcinoma","volume":"102","author":"Campbell","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"4","key":"10.1016\/j.biopha.2017.01.107_bib0350","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1016\/S0002-9440(10)63522-5","article-title":"Role of fibroblast growth factor type 1 and 2 in carbon tetrachloride-induced hepatic injury and fibrogenesis","volume":"163","author":"Yu","year":"2003","journal-title":"Am. J. Pathol."},{"issue":"12","key":"10.1016\/j.biopha.2017.01.107_bib0355","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1096\/fj.02-0319com","article-title":"Angiogenesis stimulated by PDGF-CC, a novel member in the PDGF family, involves activation of PDGFR-alphaalpha and \u2212alphabeta receptors","volume":"16","author":"Cao","year":"2002","journal-title":"FASEB J."},{"issue":"4","key":"10.1016\/j.biopha.2017.01.107_bib0360","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1111\/liv.12299","article-title":"Anti-VEGFR agents ameliorate hepatic venous dysregulation\/microcirculatory dysfunction, splanchnic venous pooling and ascites of NASH-cirrhotic rat","volume":"34","author":"Yang","year":"2014","journal-title":"Liver Int."},{"issue":"4","key":"10.1016\/j.biopha.2017.01.107_bib0365","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1002\/hep.26790","article-title":"Differential effects of sorafenib on liver versus tumor fibrosis mediated by stromal-derived factor 1 alpha\/C-X-C receptor type 4 axis and myeloid differentiation antigen-positive myeloid cell infiltration in mice","volume":"59","author":"Chen","year":"2014","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.biopha.2017.01.107_bib0370","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/j.jhep.2007.02.003","article-title":"Expression of MMPs and TIMPs in liver fibrosis \u2013 a systematic review with special emphasis on anti-fibrotic strategies","volume":"46","author":"Hemmann","year":"2007","journal-title":"J. Hepatol."},{"issue":"5","key":"10.1016\/j.biopha.2017.01.107_bib0375","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1053\/jhep.2003.50196","article-title":"Conditional tetracycline-regulated expression of TGF-beta1 in liver of transgenic mice leads to reversible intermediary fibrosis","volume":"37","author":"Ueberham","year":"2003","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.biopha.2017.01.107_bib0380","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1055\/s-2006-927388","article-title":"Mechanisms of fibrinolysis in chronic liver injury (with special emphasis on MMPs and TIMPs)","volume":"45","author":"Roderfeld","year":"2007","journal-title":"Z. Gastroenterol."},{"issue":"1","key":"10.1016\/j.biopha.2017.01.107_bib0385","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/0016-5085(95)90024-1","article-title":"Hepatic mitochondrial DNA deletion in alcoholics: association with microvesicular steatosis","volume":"108","author":"Fromenty","year":"1995","journal-title":"Gastroenterology"},{"issue":"6 (Nov\u2013Dec)","key":"10.1016\/j.biopha.2017.01.107_bib0390","first-page":"215","article-title":"Nonalcoholic fatty liver disease in the Indian subcontinent: a medical consequence of globalization?","volume":"20","author":"Sanyal","year":"2001","journal-title":"Indian J. Gastroenterol."},{"issue":"2","key":"10.1016\/j.biopha.2017.01.107_bib0395","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1586\/egh.11.11","article-title":"Mitochondrial dysfunction in nonalcoholic steatohepatitis","volume":"5","author":"Serviddio","year":"2011","journal-title":"Expert Rev. Gastroenterol. Hepatol."},{"issue":"4","key":"10.1016\/j.biopha.2017.01.107_bib0400","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1002\/hep.1840380426","article-title":"Defective hepatic mitochondrial respiratory chain in patients with nonalcoholic steatohepatitis","volume":"38","author":"Perez-Carreras","year":"2003","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.biopha.2017.01.107_bib0405","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/S0168-8278(99)80033-6","article-title":"Mitochondrial abnormalities in non-alcoholic steatohepatitis","volume":"1","author":"Caldwell","year":"1999","journal-title":"J. Hepatol."},{"issue":"1","key":"10.1016\/j.biopha.2017.01.107_bib0410","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.mito.2005.10.004","article-title":"Mitochondrial dysfunction in NASH: causes, consequences and possible means to prevent it","volume":"6","author":"Begriche","year":"2006","journal-title":"Mitochondrion"},{"issue":"1","key":"10.1016\/j.biopha.2017.01.107_bib0415","first-page":"S20","article-title":"Role of mitochondria in non-alcoholic fatty liver disease","volume":"22","author":"Pessayre","year":"2007","journal-title":"J. Gastroenterol. Hepatol."},{"issue":"17","key":"10.1016\/j.biopha.2017.01.107_bib0420","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1001\/jama.282.17.1659","article-title":"Alterations in liver ATP homeostasis in human nonalcoholic steatohepatitis: a pilot study","volume":"282","author":"Cortez-Pinto","year":"1999","journal-title":"JAMA"},{"issue":"1-2","key":"10.1016\/j.biopha.2017.01.107_bib0425","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.mam.2007.09.014","article-title":"Mitochondrial involvement in non-alcoholic steatohepatitis","volume":"29","author":"Serviddio","year":"2008","journal-title":"Mol. Aspects Med."},{"issue":"1","key":"10.1016\/j.biopha.2017.01.107_bib0430","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.freeradbiomed.2011.10.003","article-title":"Role of oxidative stress in the pathogenesis of nonalcoholic steatohepatitis","volume":"52","author":"Rolo","year":"2012","journal-title":"Free Radic. Biol. Med."},{"issue":"7","key":"10.1016\/j.biopha.2017.01.107_bib0435","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1111\/j.1365-2362.2008.01963.x","article-title":"Severe liver steatosis correlates with nitrosative and oxidative stress in rats","volume":"38","author":"Grattagliano","year":"2008","journal-title":"Eur. J. Clin. Invest."},{"issue":"5","key":"10.1016\/j.biopha.2017.01.107_bib0440","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1128\/MCB.20.5.1868-1876.2000","article-title":"The coactivator PGC-1 cooperates with peroxisome proliferator-activated receptor alpha in transcriptional control of nuclear genes encoding mitochondrial fatty acid oxidation enzymes","volume":"20","author":"Vega","year":"2000","journal-title":"Mol. Cell. Biol."},{"issue":"1","key":"10.1016\/j.biopha.2017.01.107_bib0445","first-page":"12","article-title":"The management of portal hypertension: rational basis, available treatments and future options","volume":"48","author":"Bosch","year":"2008","journal-title":"J. Hepatol."},{"issue":"10","key":"10.1016\/j.biopha.2017.01.107_bib0450","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1152\/ajpgi.00252.2011","article-title":"Effects of the combined administration of propranolol plus sorafenib on portal hypertension in cirrhotic rats","volume":"302","author":"D'Amico","year":"2012","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"issue":"3","key":"10.1016\/j.biopha.2017.01.107_bib0455","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1124\/jpet.104.079616","article-title":"Long-term treatment of bile duct-ligated rats with rapamycin (sirolimus) significantly attenuates liver fibrosis: analysis of the underlying mechanisms","volume":"313","author":"Biecker","year":"2005","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"4","key":"10.1016\/j.biopha.2017.01.107_bib0460","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1002\/hep.21785","article-title":"Reversal of portal hypertension and hyperdynamic splanchnic circulation by combined vascular endothelial growth factor and platelet-derived growth factor blockade in rats","volume":"46","author":"Fernandez","year":"2007","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.biopha.2017.01.107_bib0465","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/j.jhep.2005.09.021","article-title":"Heme oxygenase attenuates oxidative stress and inflammation, and increases VEGF expression in portal hypertensive rats","volume":"44","author":"Angermayr","year":"2006","journal-title":"J. Hepatol."},{"issue":"3","key":"10.1016\/j.biopha.2017.01.107_bib0470","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1053\/j.gastro.2003.12.012","article-title":"Anti-VEGF receptor-2 monoclonal antibody prevents portal-systemic collateral vessel formation in portal hypertensive mice","volume":"126","author":"Fernandez","year":"2004","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1016\/j.biopha.2017.01.107_bib0475","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1016\/j.jhep.2006.07.030","article-title":"Low-dose oral rapamycin treatment reduces fibrogenesis, improves liver function, and prolongs survival in rats with established liver cirrhosis","volume":"45","author":"Neef","year":"2006","journal-title":"J. Hepatol."},{"issue":"5A","key":"10.1016\/j.biopha.2017.01.107_bib0480","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1111\/j.1582-4934.2008.00218.x","article-title":"The somatostatin analogue octreotide inhibits angiogenesis in the earliest, but not in advanced, stages of portal hypertension in rats","volume":"12","author":"Mejias","year":"2008","journal-title":"J. Cell. Mol. Med."},{"issue":"1","key":"10.1016\/j.biopha.2017.01.107_bib0485","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.jhep.2005.02.022","article-title":"Inhibition of VEGF receptor-2 decreases the development of hyperdynamic splanchnic circulation and portal-systemic collateral vessels in portal hypertensive rats","volume":"43","author":"Fernandez","year":"2005","journal-title":"J. Hepatol."},{"issue":"4","key":"10.1016\/j.biopha.2017.01.107_bib0490","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1136\/gut.2005.088013","article-title":"NAD(P)H oxidase modulates angiogenesis and the development of portosystemic collaterals and splanchnic hyperaemia in portal hypertensive rats","volume":"56","author":"Angermayr","year":"2007","journal-title":"Gut"},{"issue":"4","key":"10.1016\/j.biopha.2017.01.107_bib0495","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1002\/hep.22745","article-title":"Computer-assisted image analysis of liver collagen: relationship to Ishak scoring and hepatic venous pressure gradient","volume":"49","author":"Calvaruso","year":"2009","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.biopha.2017.01.107_bib0500","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1053\/jhep.2003.50133","article-title":"Hemodynamic response to pharmacological treatment of portal hypertension and long-term prognosis of cirrhosis","volume":"37","author":"Abraldes","year":"2003","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.biopha.2017.01.107_bib0505","doi-asserted-by":"crossref","first-page":"G980","DOI":"10.1152\/ajpgi.00336.2005","article-title":"Mild increases in portal pressure upregulate vascular endothelial growth factor and endothelial nitric oxide synthase in the intestinal microcirculatory bed, leading to a hyperdynamic state","volume":"290","author":"Abraldes","year":"2006","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"issue":"41","key":"10.1016\/j.biopha.2017.01.107_bib0510","doi-asserted-by":"crossref","first-page":"6577","DOI":"10.3748\/wjg.v12.i41.6577","article-title":"Animal models of portal hypertension","volume":"12","author":"Abraldes","year":"2006","journal-title":"World J. Gastroenterol."},{"issue":"1","key":"10.1016\/j.biopha.2017.01.107_bib0515","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/j.1365-2036.2011.04896.x","article-title":"The effects of sorafenib on the portal hypertensive syndrome in patients with liver cirrhosis and hepatocellular carcinoma\u2013a pilot study","volume":"35","author":"Pinter","year":"2012","journal-title":"Aliment. Pharmacol. Ther."},{"issue":"10 (Nov)","key":"10.1016\/j.biopha.2017.01.107_bib0520","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1111\/apt.12067","article-title":"Letter: sorafenib in portal hypertension","volume":"36","author":"Procopet","year":"2012","journal-title":"Aliment. Pharmacol. Ther."},{"issue":"7","key":"10.1016\/j.biopha.2017.01.107_bib0525","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1016\/S0092-8674(00)81810-3","article-title":"Blood vessel formation: what is its molecular basis?","volume":"87","author":"Folkman","year":"1996","journal-title":"Cell"},{"issue":"4","key":"10.1016\/j.biopha.2017.01.107_bib0530","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1038\/74651","article-title":"Mechanisms of angiogenesis and arteriogenesis","volume":"6","author":"Carmeliet","year":"2000","journal-title":"Nat. Med."},{"issue":"5","key":"10.1016\/j.biopha.2017.01.107_bib0535","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1002\/hep.20193","article-title":"Angiogenesis in chronic inflammatory liver disease","volume":"39","author":"Medina","year":"2004","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.biopha.2017.01.107_bib0540","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1016\/j.jhep.2008.12.011","article-title":"Angiogenesis in liver disease","volume":"50","author":"Fernandez","year":"2009","journal-title":"J. Hepatol."},{"issue":"2","key":"10.1016\/j.biopha.2017.01.107_bib0545","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1053\/j.gastro.2008.04.010","article-title":"Platelet-derived growth factor signaling through ephrin-b2 regulates hepatic vascular structure and function","volume":"135","author":"Semela","year":"2008","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1016\/j.biopha.2017.01.107_bib0550","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/S0168-8278(98)80287-0","article-title":"The postprandial portal flow is related to the severity of portal hypertension and liver cirrhosis","volume":"28","author":"Ludwig","year":"1998","journal-title":"J. Hepatol."},{"issue":"3","key":"10.1016\/j.biopha.2017.01.107_bib0555","doi-asserted-by":"crossref","first-page":"667","DOI":"10.2214\/ajr.176.3.1760667","article-title":"Hepatic perfusion parameters in chronic liver disease: dynamic CT measurements correlated with disease severity","volume":"176","author":"Van Beers","year":"2001","journal-title":"AJR Am. J. Roentgenol."},{"issue":"3","key":"10.1016\/j.biopha.2017.01.107_bib0560","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1016\/j.bbrc.2009.01.160","article-title":"Thalidomide decreases intrahepatic resistance in cirrhotic rats","volume":"380","author":"Yang","year":"2009","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"2","key":"10.1016\/j.biopha.2017.01.107_bib0565","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1002\/hep.1840050215","article-title":"Temporal relationship between hyperaldosteronism, sodium retention and ascites formation in rats with experimental cirrhosis","volume":"5","author":"Jimenez","year":"1985","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.biopha.2017.01.107_bib0570","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1053\/jhep.2002.31250","article-title":"Hepatic encephalopathy-definition, nomenclature, diagnosis, and quantification: final report of the working party at the 11th World Congresses of Gastroenterology, Vienna, 1998","volume":"35","author":"Ferenci","year":"2002","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.biopha.2017.01.107_bib0575","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1055\/s-2007-1007240","article-title":"Brain edema and hepatic encephalopathy","volume":"16","author":"Cordoba","year":"1996","journal-title":"Semin. Liver Dis."},{"issue":"12","key":"10.1016\/j.biopha.2017.01.107_bib0580","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1111\/eci.12006","article-title":"The influence of sorafenib on hepatic encephalopathy and the mechanistic survey in cirrhotic rats","volume":"42","author":"Hsu","year":"2012","journal-title":"Eur. J. Clin. Invest."},{"issue":"5","key":"10.1016\/j.biopha.2017.01.107_bib0585","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1097\/MCG.0b013e31818ddfc6","article-title":"Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma in consideration of concomitant stage of liver cirrhosis","volume":"43","author":"Worns","year":"2009","journal-title":"J. Clin. Gastroenterol."},{"issue":"2","key":"10.1016\/j.biopha.2017.01.107_bib0590","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1002\/cncr.24029","article-title":"Phase 2 open-label study of single-agent sorafenib in treating advanced hepatocellular carcinoma in a hepatitis B-endemic Asian population: presence of lung metastasis predicts poor response","volume":"115","author":"Yau","year":"2009","journal-title":"Cancer"},{"issue":"8 (Aug)","key":"10.1016\/j.biopha.2017.01.107_bib0595","first-page":"2162","article-title":"Sorafenib-induced liver failure","volume":"103","author":"Schramm","year":"2008","journal-title":"Am. J. gastroenterol."},{"issue":"1 (Jan)","key":"10.1016\/j.biopha.2017.01.107_bib0600","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1038\/ajg.2008.41","article-title":"Acute hepatitis in a patient with cirrhosis and hepatocellular carcinoma treated with sorafenib","volume":"104","author":"Llanos","year":"2009","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.biopha.2017.01.107_bib0605","article-title":"Opposing roles of VEGF during liver fibrosis progression and resolution","volume":"56","author":"Yang","year":"2012","journal-title":"Hepatology"},{"issue":"107","key":"10.1016\/j.biopha.2017.01.107_bib0610","first-page":"971","article-title":"Induction of HGF and VEGF in hepatic regeneration after hepatotoxin-Induced cirrhosis in mice","volume":"58","author":"Tekkesin","year":"2011","journal-title":"Hepatogastroenterology"}],"container-title":["Biomedicine & Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332216325057?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332216325057?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T12:17:35Z","timestamp":1778242655000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332216325057"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4]]},"references-count":122,"alternative-id":["S0753332216325057"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2017.01.107","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2017,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sorafenib: A potential therapeutic drug for hepatic fibrosis and its outcomes","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2017.01.107","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}